Systemic Lupus Erythematosus: key endpoint results by drug

The key endpoints of Systemic Lupus Erythematosus trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Systemic Lupus Erythematosus page.

SRI-4

SRI-4 in Systemic Lupus Erythematosus: 8 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abatacept29%22.9%+6.1wk 24 · n 31NCT02270957 Phase 2, secondary
Anifrolumab36.1%40.2%−4.1300 mg · wk 52 · n 180NCT02446912 Phase 3, primary
baricitinib47.1%45.6%+1.54 mg · wk 52 · n 258NCT03616964 Phase 3, primary
deucravacitinib44.9%34.4%+10.512 mg · wk 32 · n 89NCT03252587 Phase 2, primary
Litifilimab56.3%28.6%+27.7450 mg · wk 24 · n 64NCT02847598 Phase 2, secondary
rezpegaldesleukin27.4%29.7%−2.3High dose · wk 24 · n 73NCT04433585 Phase 2, secondary
upadacitinib54.4%38.7%+15.760 mg/30 mg · wk 24 · n 68NCT03978520 Phase 2, secondary
ustekinumab61.7%33.3%+28.4wk 24 · n 60NCT02349061 Phase 2, primary

Drugs checked with no result here: 54 not reported, 2 trial running, 2 not posted.

BICLA

BICLA in Systemic Lupus Erythematosus: 6 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abatacept25.8%22.9%+2.9wk 24 · n 31NCT02270957 Phase 2, primary
Anifrolumab47.8%31.3%+16.5300 mg · wk 52 · n 180NCT02446899 Phase 3, primary
deucravacitinib36%25.6%+10.412 mg · wk 48 · n 89NCT03252587 Phase 2, secondary
rezpegaldesleukin20%30%−10High dose · wk 24 · n 60NCT04433585 Phase 2, secondary
upadacitinib54.4%42.7%+11.760 mg/30 mg · wk 24 · n 68NCT03978520 Phase 2, secondary
ustekinumab35%33.3%+1.7wk 24 · n 60NCT02349061 Phase 2, secondary

Drugs checked with no result here: 55 not reported, 3 trial running, 2 not posted.

CLASI-50

CLASI-50 in Systemic Lupus Erythematosus: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Anifrolumab41.4%25.9%+15.5300 mg · wk 12 · n 58NCT02446912 Phase 3, secondary
baricitinib58%66.1%−8.14 mg · wk 52 · n 50NCT03616964 Phase 3, secondary
deucravacitinib62.1%16.7%+45.412 mg · wk 48 · n 29NCT03252587 Phase 2, secondary
Litifilimab37.5%12.1%+25.4450 mg · wk 12 · n 48NCT02847598 Phase 2, secondary

Drugs checked with no result here: 57 not reported, 3 trial running, 2 not posted.

Steroid sparing

Steroid sparing in Systemic Lupus Erythematosus: 2 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Anifrolumab40.8%32.4%+8.4300 mg · wk 52 · n 103NCT02446912 Phase 3, secondary
baricitinib34.3%31.7%+2.64 mg · wk 52 · n 105NCT03616964 Phase 3, secondary

Drugs checked with no result here: 57 not reported, 5 trial running, 2 not posted.

  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 66 approved or late-stage drugs with a featured trial in Systemic Lupus Erythematosus were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.